<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863888</url>
  </required_header>
  <id_info>
    <org_study_id>LPS13539</org_study_id>
    <secondary_id>U1111-1139-8802</secondary_id>
    <nct_id>NCT01863888</nct_id>
  </id_info>
  <brief_title>Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis</brief_title>
  <acronym>TERI-DYNAMIC</acronym>
  <official_title>Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing&#xD;
      forms of multiple sclerosis as compared with baseline values and those of a reference&#xD;
      population of untreated healthy subjects.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess if Teriflunomide treatment results in biased T cell clonal diversity. To assess the&#xD;
      effect of Teriflunomide on the function of peripheral blood mononuclear cells (proliferation&#xD;
      and cytokine production in situ).&#xD;
&#xD;
      To assess the circulating cytokines profile in the serum of Relapsing Multiple Sclerosis&#xD;
      (RMS) patients during a 24-week treatment versus baseline and healthy controls.&#xD;
&#xD;
      To assess the reversibility of all parameter changes in patients who discontinue treatment&#xD;
      after accelerated elimination procedure with cholestyramine or activated charcoal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for patients is 32 weeks which includes 4 weeks for screening, 24&#xD;
      weeks for treatment and 4 weeks for follow-up. An extension of the study is proposed until&#xD;
      Teriflunomide is commercially available in the country where patient lives.&#xD;
&#xD;
      The duration of the study for healthy volunteers is 25 weeks which includes only one week for&#xD;
      screening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Lymphocyte subset parameters as measured by flow cytometry</measure>
    <time_frame>At 12 weeks and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biased T cell clonal repertoire based T cell receptor (TCR) spectratyping</measure>
    <time_frame>At 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum cytokine as measured by multicytokine array tool</measure>
    <time_frame>At 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mitogen/TCR-specific T cell proliferation as measured by flow cytometry</measure>
    <time_frame>At 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>teriflunomide (HMR1726)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference population</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriflunomide HMR1726</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>teriflunomide (HMR1726)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholestyramine</intervention_name>
    <description>Pharmaceutical form:powder Route of administration: oral</description>
    <arm_group_label>teriflunomide (HMR1726)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>charcoal</intervention_name>
    <description>Pharmaceutical form:granule Route of administration: oral</description>
    <arm_group_label>teriflunomide (HMR1726)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients (male and female) with relapsing forms of multiple sclerosis meeting McDonald&#xD;
        criteria for MS at the screening visit and having either one of the following treatment&#xD;
        status:&#xD;
&#xD;
          -  Naïve to disease modifying (DM) treatment or no DM treatment for more than 2 years&#xD;
&#xD;
          -  Or currently (not more than 3 months interruption) on MS therapy with IFN β-1 or&#xD;
             Glatiramer acetate and a period of at least 2 weeks without IFN β-1 or Glatiramer&#xD;
             acetate before switching to teriflunomide.&#xD;
&#xD;
        Male and female patients, between 18 and 56 years of age, exclusive.&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
        Male and female subjects, between 18 and 56 years of age, exclusive. Body weight between&#xD;
        50.0 and 95.0 kg, inclusive, if male; and between 40.0 and 85.0 kg, inclusive, if female,&#xD;
        body mass index between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
        Certified as healthy by a comprehensive clinical assessment (detailed medical history and&#xD;
        complete physical examination).&#xD;
&#xD;
        Normal vital signs after 10 minutes resting in supine position:&#xD;
&#xD;
          -  95 mmHg &lt; systolic blood pressure (SBP) &lt;140 mmHg&#xD;
&#xD;
          -  45 mmHg &lt; diastolic blood pressure (DBP) &lt;90 mmHg&#xD;
&#xD;
          -  40 bpm &lt; heart rate (HR) &lt;100 bpm Normal standard 12-lead electrocardiogram (ECG)&#xD;
             after 10 minutes resting in supine position; 120 ms &lt; PR &lt;220 ms, QRS &lt;120 ms, QTc ≤&#xD;
             430 ms if male, ≤ 450 ms if female.&#xD;
&#xD;
        Laboratory parameters within the normal range (or defined screening threshold for the&#xD;
        Investigator site), unless the Investigator considers an abnormality to be clinically&#xD;
        irrelevant for healthy subjects; however liver function parameter(s) should not exceed the&#xD;
        upper laboratory norm.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Did not consent to HIV testing (the specifics of informed consent process for the HIV&#xD;
        testing should be done in accordance with local guidelines).&#xD;
&#xD;
        A relapse within 30 days prior to screening. Clinically relevant cardiovascular,&#xD;
        neurological, endocrine, or other major systemic disease making implementation of the&#xD;
        protocol or interpretation of the study results difficult or that would put the patient at&#xD;
        risk by participating in the study.&#xD;
&#xD;
        Patients with a congenital or acquired severe immunodeficiency, a history of cancer (except&#xD;
        for basal or squamous cell skin lesions which have been surgically excised, with no&#xD;
        evidence of metastasis), lymphoproliferative disease, or any patient who has received&#xD;
        lymphoid irradiation.&#xD;
&#xD;
        Human immunodeficiency virus (HIV) positive patients. Known history of active tuberculosis&#xD;
        not adequately treated or positive QuantiFERON TB Gold test.&#xD;
&#xD;
        Hypoproteinemia (eg, in case of severe liver disease or nephrotic syndrome) with serum&#xD;
        albumin &lt;3.0 g/dL.&#xD;
&#xD;
        Moderate to severe impairment of renal function, as shown by serum creatinine &gt;133 μmol/L&#xD;
        (or &gt;1.5 mg/dL).&#xD;
&#xD;
        Patients with significantly impaired bone marrow function or significant anemia,&#xD;
        leukopenia, or thrombocytopenia.&#xD;
&#xD;
        Acute or chronic infection. Liver function impairment or persisting elevations &gt;1.5ULN&#xD;
        (confirmed by retest) of serum glutamic pyruvic transaminase/ alanine aminotransferase&#xD;
        (SGPT/ALT), serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST),&#xD;
        or direct bilirubin greater than 1.5-fold the upper limit of normal.&#xD;
&#xD;
        Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to&#xD;
        screening.&#xD;
&#xD;
        Prior or concomitant use of cytokine therapy or intravenous immunoglobulins in the 3 months&#xD;
        prior to screening.&#xD;
&#xD;
        Prior use of alemtuzumab or cladribine. Prior use (within 1 year) of fingolimod (Gylenia®).&#xD;
        Prior use (within 2 years) of mitoxantrone, natalizumab (Tysabri®), or immunosuppressant&#xD;
        agents (i.e. azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate).&#xD;
&#xD;
        Prior treatment with teriflunomide, and prior or concomitant use of leflunomide (ARAVA®) or&#xD;
        hypersensitivity to any of the other ingredients or excipients of the investigational&#xD;
        product.&#xD;
&#xD;
        Prior use of any investigational drug in the 6 months preceding screening. Pregnant or&#xD;
        breast-feeding women. Women of childbearing potential not utilizing effective contraceptive&#xD;
        method and /or women of childbearing potential who are unwilling to or unable to be tested&#xD;
        for pregnancy.&#xD;
&#xD;
        Known history of hypersensitivity to teriflunomide or leflunomide. Persisting elevations&#xD;
        (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of&#xD;
        normal.&#xD;
&#xD;
        Known history of chronic pancreatic disease or pancreatitis.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Overpelt</city>
        <zip>3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Sijsele-Damme</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-003</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-004</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-005</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-007</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-001</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-002</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

